United Therapeutics (STU:UTH) Ending Cash Position : €1,400 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is United Therapeutics Ending Cash Position?

United Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 was €1,400 Mil.

United Therapeutics's quarterly Ending Cash Position increased from Mar. 2024 (€1,151 Mil) to Jun. 2024 (€1,259 Mil) and increased from Jun. 2024 (€1,259 Mil) to Sep. 2024 (€1,400 Mil).

United Therapeutics's annual Ending Cash Position increased from Dec. 2021 (€792 Mil) to Dec. 2022 (€907 Mil) and increased from Dec. 2022 (€907 Mil) to Dec. 2023 (€1,107 Mil).

United Therapeutics Ending Cash Position Historical Data

The historical data trend for United Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Ending Cash Position Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

664.56

607.21

791.90

907.37

1,107.46

United Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial															1,037.92	1,107.46	1,151.38	1,259.45	1,400.06

United Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

United Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	881.42	+	226.041
	=	1,107

United Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1221.486	+	178.578
	=	1,400

United Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany U2TH34:Brazil

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics Headlines

No Headlines